@article {O{\textquoteright}Leary2021.09.16.21263687, author = {Mary F. O{\textquoteright}Leary and Sarah R. Jackman and Vlad R. Sabou and Matthew I Campbell and Jonathan C. Y. Tang and John Dutton and Joanna L. Bowtell}, title = {Shatavari Supplementation in Postmenopausal Women Improves Handgrip Strength and Increases Vastus Lateralis Myosin Regulatory Light Chain Phosphorylation But Does Not Alter Markers of Bone Turnover: A Randomised Controlled Trial}, elocation-id = {2021.09.16.21263687}, year = {2021}, doi = {10.1101/2021.09.16.21263687}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Shatavari has long been used as an Ayurvedic herb for women{\textquoteright}s health, but empirical evidence for its effectiveness has been lacking. Shatavari contains phytoestrogenic compounds that bind to the estradiol receptor, and may therefore benefit postmenopausal women since postmenopausal estradiol deficiency contributes to sarcopenia and osteoporosis.Methods In a randomised double-blind trial, 20 postmenopausal women (68.5 {\textpm} 6 y) ingested either placebo (N=10) or shatavari (N=10; 1000 mg/d, equivalent to 26,500 mg/d fresh weight shatavari) for 6 weeks. Handgrip and knee extensor strength were measured at baseline and at 6 weeks. Vastus lateralis (VL) biopsy samples were obtained. Data are presented and analysed (t test/Mann Whitney U) as difference scores (Week 6 {\textendash} baseline, median {\textpm} interquartile range).Results Handgrip, (but not knee extensor) strength was improved by shatavari supplementation (shatavari +0.7 {\textpm} 1.1 kg, placebo -0.4 {\textpm} 1.3 kg; p=0.04). Myosin regulatory light chain phosphorylation, a known marker of improved myosin contractile function, was increased in VL following shatavari supplementation (immunoblotting; placebo -0.08 {\textpm} 0.5 a.u. shatavari +0.3 {\textpm} 1 arbitrary units (a.u.); p=0.03). Shatavari increased phosphorylation of Aktser473 (Aktser473 (placebo -0.6 {\textpm} 0.6 a.u. shatavari +0.2 {\textpm} 1.3 a.u; p=0.03) in VL. Shatavari supplementation did not alter plasma markers of bone turnover (P1NP, β-CTX) and stimulation of human osteoblasts with pooled sera (N=8 per condition) from placebo and shatavari supplementation conditions did not alter cytokine or metabolic markers of osteoblast activity.Conclusions Shatavari may improve muscle function and contractility via myosin conformational change and warrants further investigation of its utility in conserving musculoskeletal function in postmenopausal women.Trial Registration Retrospectively registered at clinicaltrials.gov as NCT05025917 on 30/08/21.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05025917. This study was not prospectively registered as it is a study of a non-regulated nutritional intervention.Funding StatementThis work was supported by Pukka Herbs Ltd. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Exeter{\textquoteright}s Sport and Health Sciences Research Ethics Committee (190206/B/01).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.}, URL = {https://www.medrxiv.org/content/early/2021/09/20/2021.09.16.21263687}, eprint = {https://www.medrxiv.org/content/early/2021/09/20/2021.09.16.21263687.full.pdf}, journal = {medRxiv} }